Salmonella enterica serotype choleraesuis:: Epidemiology, pathogenesis, clinical disease, and treatment

Nontyphoid Salmonella strains are important causes of reportable food-borne infection. Among more than 2, 000 serotypes, Salmonella enterica serotype Choleraesuis shows the highest predilection to cause systemic injections in humans. The most feared complication of serotype Cholearesuis bacteremia in adults is the development of mycotic aneurysm, which previously was almost uniformally fatal. The advances in diagnostic techniques, surgical care, and antimicrobial therapy have greatly improved the survival of these patients. However; the recent emergence of serotype Choleraesuis that is resistant to ampicillin, chloramphenicol, trimethoprim-sulfamethoxazole, and notably, fluoroquinolone antibiotics has aroused concern about the use of these agents for the empirical treatment of systemic infection caused by this organism. In view of the serious implications of the situation, the chain of transmission and mechanism of resistance should be carefully studied to reduce the spread of infection and threat to human health. To date, there are no vaccines available to prevent serotype Choleracsuis infections in humans. The availability, in the near future, of the genome sequence of serotype Choleracsuis will facilitate the development of effective vaccines as well as the discovery of new targets for novel antimicrobial agents.